<SEC-DOCUMENT>0001650664-25-000123.txt : 20250812
<SEC-HEADER>0001650664-25-000123.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812160342
ACCESSION NUMBER:		0001650664-25-000123
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Editas Medicine, Inc.
		CENTRAL INDEX KEY:			0001650664
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				464097528
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37687
		FILM NUMBER:		251206545

	BUSINESS ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
		BUSINESS PHONE:		617-401-9000

	MAIL ADDRESS:	
		STREET 1:		11 HURLEY ST.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02141
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>edit-20250812.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0dc87832-d86a-4d49-8beb-0140cb219eff,g:6c29f98a-c18a-44c6-94bd-cfb6754f5ca3,d:9a63bbd39ee1488590a65cb1c5ecdf31-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>edit-20250812</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001650664</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="edit-20250812.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001650664</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9a63bbd39ee1488590a65cb1c5ecdf31_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">of The Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;12, 2025</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Editas Medicine, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">_________________________________________________________________________________________</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:39.719%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37687</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-4097528</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">11 Hurley Street</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Cambridge,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Massachusetts</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">02141</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">401-9000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">EDIT</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">o</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9a63bbd39ee1488590a65cb1c5ecdf31_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-23">August&#160;12, 2025</ix:nonNumeric>, Editas Medicine, Inc. (the &#8220;Company&#8221;) issued a press release announcing financial results for the fiscal quarter ended June 30, 2025 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;Filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div id="i9a63bbd39ee1488590a65cb1c5ecdf31_10"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:31.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.84pt">Exhibits</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="editasmedicinepressrelease.htm">Press release issued by the Company on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="editasmedicinepressrelease.htm">August 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="editasmedicinepressrelease.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="editasmedicinepressrelease.htm">, 2025*</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.5pt">This exhibit shall be deemed to be furnished and not filed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i9a63bbd39ee1488590a65cb1c5ecdf31_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">EDITAS MEDICINE, INC.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-24">August&#160;12, 2025</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Amy Parison</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Amy Parison</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>editasmedicinepressrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i285b9cf834ce4cb2acf43be3ae1c218d_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:162px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Editas Medicine Announces Second Quarter 2025 Results and Business Updates</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Company to select lead development candidate in September&#59; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">First IND&#47;CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol Myers Squibb, triggering milestone payment to Editas   </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Presented data at ASGCT, TIDES, and EHA that validate differentiated potential of Editas&#8217; gene upregulation strategy and</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> delivery platform technology   </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Strong cash position with operational runway into the second quarter of 2027</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">CAMBRIDGE, Mass., August&#160;12, 2025 &#8211; Editas Medicine, Inc. (Nasdaq&#58; EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the second quarter 2025 and provided business updates.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;We made good progress in executing our strategy in the second quarter, driving towards our goal of nominating our first</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> in vivo </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">development candidate, which we plan to select in September,&#8221; said Gilmore O&#8217;Neill, M.B., M.M.Sc., President and Chief Executive Officer of Editas Medicine. &#8220;We are on track to file an IND for our lead program by mid-2026 and achieve human proof-of-concept by the end of 2026. In addition, we announced new proof-of-concept preclinical data for our </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">programs during the second quarter, which we believe support the potential of our LNP platform and differentiated upregulation strategy to transform the future of disease treatment through gene editing.&#8221;  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Recent Achievements and Outlook </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Editas presented new preclinical proof-of-concept data in both hematopoietic stem cells (HSCs) and liver cells in the second quarter. The Company will select the lead candidate to advance towards human proof-of-concept in September.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Liver Cells </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">In May, Editas shared preclinical proof-of-concept data at the American Society of Gene and Cell Therapy (ASGCT) annual meeting and the TIDES annual meeting for an undisclosed liver target using </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> CRISPR editing to upregulate target protein expression and reduce a disease-associated biomarker in a relevant mouse disease model.   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Hematopoietic Stem Cells </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">In June, Editas shared new </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> data demonstrating therapeutically relevant levels of HBG1&#47;2 promoter editing in hematopoietic stem cells with a single dose of novel targeted lipid nanoparticle (tLNP) in NHPs at the European Hematology Association (EHA) 2025 Congress.   </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Platform Enhancements and Other Cells&#47;Tissues </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Editas shared preclinical data demonstrating</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> gene editing capabilities with its proprietary tLNP at ASGCT.   </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">The Company remains on track to establish and disclose a further target cell type&#47;tissue by the end of 2025.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Other Corporate Highlights </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Partnership Update </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">As part of the Company&#8217;s collaboration agreement with Bristol Myers Squibb, the first IND&#47;CTA was accepted for the CD19 HD Allo CAR T program, triggering a milestone payment to Editas. The achievement marks the first time Editas&#8217; in-house developed technology will be used clinically in the allogenic CAR-T setting for the potential treatment of autoimmune disease. In May 2024, Editas announced the extension of its collaboration with Bristol Myers Squibb, under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Second Quarter 2025 Financial Results</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketabl</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">e securities as of June&#160;30, 2025 were $178.5 million compared to $269.9 million as of December&#160;31, 2024. The Company expects that the existing cash, cash equivalents, marketable securities, and the retained portions of the payments payable under its license agreement with Vertex Pharmaceuticals, will enable the Company to fund its operating expenses and capital expenditure requirements into the second quarter of 2027.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">Second Quarter 2025</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">For the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">three months ended June 30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">, net loss attributable to common stockholders was </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$53.2 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">, or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$0.63</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> per share, compared to net loss of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$67.6 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">, or </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$0.82</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> per share, for the same period in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Collaboration and other research and development revenues </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">increased</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$3.6 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> for the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">three months ended June 30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">, compared to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$0.5 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> for the same period in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">The increase is primarily attributable to the recognition of revenue related to specified deliverables that were achieved in the second quarter of 2025.</font></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Research and development expenses </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">decreased</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> by </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$38.0 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$16.2 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> for the </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">three months ended June 30, 2025</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">, compared to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">$54.2 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> for the same period in </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> The decrease is primarily related to clinical and manufacturing costs related to discontinuation of the clinical development of the Company&#8217;s reni-cel program initiated in December 2024, partially offset by costs attributable to </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> research and discovery.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">General and administrative expenses decreased by $5.3 million to $12.9 million for the three months ended June 30, 2025, compared to $18.2 million for the same period in 2024. The decrease is primarily attributable to employee-related expenses related to reduced headcount associated with the reduction in workforce due to the discontinuation of the clinical development of the Company&#8217;s reni-cel program initiated in December 2024.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.8pt">Restructuring and impairment charges were $26.1 million for the three months ended June 30, 2025, compared to no such charges for the same period in 2024.  The restructuring and impairment charges were related to the discontinuation of the clinical development of the Company&#8217;s reni-cel program initiated in December 2024, the related workforce reduction, associated impairment charges for laboratory and manufacturing equipment related to the reni-cel program, and the acceleration in expense due to changes in useful life estimates for leasehold improvements, software and a right of use asset associated with the Company&#8217;s reni-cel program.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:112%">About Editas Medicine </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR&#47;Cas12a and CRISPR&#47;Cas9 genome editing systems into a robust pipeline of transformative </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute&#8217;s Cas12a patent estate and Broad Institute and Harvard University&#8217;s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Forward-Looking Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8216;&#8216;anticipate,&#8217;&#8217; &#8216;&#8216;believe,&#8217;&#8217; &#8216;&#8216;continue,&#8217;&#8217; &#8216;&#8216;could,&#8217;&#8217; &#8216;&#8216;estimate,&#8217;&#8217; &#8216;&#8216;expect,&#8217;&#8217; &#8216;&#8216;intend,&#8217;&#8217; &#8216;&#8216;may,&#8217;&#8217; &#8216;&#8216;plan,&#8217;&#8217; &#8216;&#8216;potential,&#8217;&#8217; &#8216;&#8216;predict,&#8217;&#8217; &#8216;&#8216;project,&#8217;&#8217; &#8216;&#8216;target,&#8217;&#8217; &#8216;&#8216;should,&#8217;&#8217; &#8216;&#8216;would,&#8217;&#8217; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the initiation, timing, progress and results of the Company&#8217;s preclinical studies and its research and development programs, including the Company&#8217;s expectation to select a lead development candidate in September 2025, achieve human proof-of-concept by year-end 2026, and establish and disclose a further </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%"> target cell type&#47;tissue by the end of 2025&#59; the timing for the Company&#8217;s receipt and presentation of data from its preclinical studies&#59; the potential of, and expectations for, the Company&#8217;s </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">in vivo </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">product candidates&#59; the timing or likelihood of regulatory filings and approvals, including filing an IND by mid-2026&#59; and the Company&#8217;s expectations regarding cash runway into the second quarter of 2027. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including&#58; uncertainties inherent in the initiation and completion of preclinical studies&#59; availability and timing of results from preclinical studies&#59; expectations for regulatory approvals to conduct trials&#59; and the availability of funding sufficient for the Company&#8217;s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption &#8220;Risk Factors&#8221; included in the Company&#8217;s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company&#8217;s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company&#8217;s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements. </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i285b9cf834ce4cb2acf43be3ae1c218d_4"></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">EDITAS MEDICINE, INC.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">Consolidated Statement of Operations</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">(amounts in thousands, except share and per share data)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">(Unaudited)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br>June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and other research and development revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$8,236</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1,649</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">16,181&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,210&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">42,774</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">102,997</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12,859&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">18,206&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,234</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">37,545</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring and impairment charges</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">26,082&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">66,935</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">55,122&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">72,416&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">135,943</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">140,542</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(51,544)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(71,903)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(127,707)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(138,893)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,758)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,183)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest related to sale of future revenues</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(2,020)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(4,236)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,297&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,803</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,331</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,691)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,296&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(1,616)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">9,336</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(53,235)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(67,607)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$(129,323)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$(129,557)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.63)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(0.82)</font></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$(1.54)</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$(1.58)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">84,412,200</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82,310,368</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">83,737,382</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">82,124,603</font></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i285b9cf834ce4cb2acf43be3ae1c218d_7"></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">EDITAS MEDICINE, INC.</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">Selected Consolidated Balance Sheet Items</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">(amounts in thousands)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.927%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and marketable securities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">178,501&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">269,913&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">116,859&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">212,090&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">210,581&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">341,589</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,204&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">54,204</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">19,189&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">134,274</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:139%">###</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:139%">Media and Investor Contact&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ir&#64;editasmed.com</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">media&#64;editasmed.com   </font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>edit-20250812.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0dc87832-d86a-4d49-8beb-0140cb219eff,g:6c29f98a-c18a-44c6-94bd-cfb6754f5ca3-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:edit="http://www.editasmedicine.com/20250812" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.editasmedicine.com/20250812">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20250812_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20250812_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="edit-20250812_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.editasmedicine.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>edit-20250812_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0dc87832-d86a-4d49-8beb-0140cb219eff,g:6c29f98a-c18a-44c6-94bd-cfb6754f5ca3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="edit-20250812.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_9345f233-dec0-41ca-834a-934612e1aca8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_5d381c34-cf6a-454e-a663-a2e0f347ba03" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_9345f233-dec0-41ca-834a-934612e1aca8" xlink:to="loc_dei_DocumentInformationTable_5d381c34-cf6a-454e-a663-a2e0f347ba03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5603d546-16f4-45a4-978f-c2bcc5627f92" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_9345f233-dec0-41ca-834a-934612e1aca8" xlink:to="loc_dei_DocumentPeriodEndDate_5603d546-16f4-45a4-978f-c2bcc5627f92" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>edit-20250812_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0dc87832-d86a-4d49-8beb-0140cb219eff,g:6c29f98a-c18a-44c6-94bd-cfb6754f5ca3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SolicitingMaterial_fa7f0dba-503d-4a39-b142-27292c4b18ff_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_b145481d-3856-430f-a32f-01b5cf3cfa2a_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_22d9c389-052f-45b3-b4e5-5cf4ea96fa0f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_a2baf8b1-b2bc-4e59-86c5-855eace077a1_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cb4db544-ca36-4dff-a071-458b1cc0e776_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_d557979b-0f50-4118-874f-7a02d1094f74_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_866ff8c9-436a-46c0-93b1-fc5e4988c5e8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8d248c47-5851-4031-a67c-430d543f4cdf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3ee0ab6c-9156-43c7-9e4c-b33323f5733e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d3846186-7388-4e35-81f7-d55ce3514708_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d5923d8d-175a-42f1-b5b9-1b121a1f1ba9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5c1aa7bd-4f3b-4240-bedf-e3ae0c32fc37_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_017357e0-a14e-4a76-8d15-53e7db2cb5d5_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_177cb8e7-411c-4667-8533-e61beee6ca07_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_7ed51f95-adf5-4acb-80be-0d6fb49c97a6_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_075a7681-4d1a-4a8a-94bf-64cabf1d5ec0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_e6446a31-68bd-4f98-beb0-2e1becc22647_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b306cbc9-6384-4895-8c84-af3c9a8a3a6d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4124f02d-674f-4fa7-a58e-6aa49ee9fdef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f437ffa4-3f48-435c-a2ad-e278fcdbb971_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_46a3b477-3df0-49e2-8f8f-7bb446708adf_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_de4506a7-23c5-42e7-a012-988b5488efe8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_150d11dc-8187-4b03-8029-c533243815b6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c3d6d879-21aa-401c-a2bc-289039ea8a4e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fbce8288-aa10-4ed7-bfd4-2e0e50ebc42b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>edit-20250812_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:0dc87832-d86a-4d49-8beb-0140cb219eff,g:6c29f98a-c18a-44c6-94bd-cfb6754f5ca3-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="edit-20250812.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.editasmedicine.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1c2dd97b-db38-4bf1-8f3c-d46d2cd48d8a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_DocumentType_1c2dd97b-db38-4bf1-8f3c-d46d2cd48d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_46d34cd3-6242-4beb-aa6b-aa49b9f4e0fb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_DocumentPeriodEndDate_46d34cd3-6242-4beb-aa6b-aa49b9f4e0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2ec9e391-f1e3-442f-9d01-fb37ccecf223" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityFileNumber_2ec9e391-f1e3-442f-9d01-fb37ccecf223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5bba74d5-7bbf-4670-a0da-bae882232195" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityRegistrantName_5bba74d5-7bbf-4670-a0da-bae882232195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3a6ca718-1858-4e88-9ae0-78b95e054c62" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3a6ca718-1858-4e88-9ae0-78b95e054c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4b5872de-c90d-4946-bbf1-67abdfce0f77" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityTaxIdentificationNumber_4b5872de-c90d-4946-bbf1-67abdfce0f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_576489e3-11e4-4af6-aaab-fa13ad963512" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityAddressAddressLine1_576489e3-11e4-4af6-aaab-fa13ad963512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ec28e83b-56bd-4045-be73-314c7166698b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityAddressCityOrTown_ec28e83b-56bd-4045-be73-314c7166698b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_38727f04-eaa0-41a0-bf0a-f46ceb2db5ad" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityAddressStateOrProvince_38727f04-eaa0-41a0-bf0a-f46ceb2db5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f2ae4431-0e5d-4346-848e-225b85a84a7f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityAddressPostalZipCode_f2ae4431-0e5d-4346-848e-225b85a84a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9dc1b0a7-605c-478c-b519-0325825407ba" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_CityAreaCode_9dc1b0a7-605c-478c-b519-0325825407ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b9776a22-5d1a-4294-a3c8-dfd3b705b3f9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_LocalPhoneNumber_b9776a22-5d1a-4294-a3c8-dfd3b705b3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_da256a37-d760-469b-bceb-2dc30a0d826d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_WrittenCommunications_da256a37-d760-469b-bceb-2dc30a0d826d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a53805a1-8541-45a8-845f-d55467cacc1e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_SolicitingMaterial_a53805a1-8541-45a8-845f-d55467cacc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_78cf4647-e548-450d-8c60-3289dd72cff6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_PreCommencementTenderOffer_78cf4647-e548-450d-8c60-3289dd72cff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a74e778c-11d6-4d59-a77d-38b0cd987f72" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a74e778c-11d6-4d59-a77d-38b0cd987f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_12838efa-826a-4db4-8b7c-d2f4dccff0dc" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_Security12bTitle_12838efa-826a-4db4-8b7c-d2f4dccff0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f55839af-4d04-4b02-94a0-4cace04912c8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_TradingSymbol_f55839af-4d04-4b02-94a0-4cace04912c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_47267a56-c0f2-4d71-aed3-ad7976df6e4b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_SecurityExchangeName_47267a56-c0f2-4d71-aed3-ad7976df6e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c249d469-9f67-4dec-9f6d-e450b95cd7dd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityEmergingGrowthCompany_c249d469-9f67-4dec-9f6d-e450b95cd7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a0bde7c2-6644-4f37-b658-1f35f9afaed3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_EntityCentralIndexKey_a0bde7c2-6644-4f37-b658-1f35f9afaed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9324138a-870e-4e58-b63e-56e66b5dfea4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_AmendmentFlag_9324138a-870e-4e58-b63e-56e66b5dfea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_5d381c34-cf6a-454e-a663-a2e0f347ba03" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_26860f9b-d5f3-4c75-ab8e-02a381fda057" xlink:to="loc_dei_DocumentInformationTable_5d381c34-cf6a-454e-a663-a2e0f347ba03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_9345f233-dec0-41ca-834a-934612e1aca8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_5d381c34-cf6a-454e-a663-a2e0f347ba03" xlink:to="loc_dei_DocumentInformationLineItems_9345f233-dec0-41ca-834a-934612e1aca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5603d546-16f4-45a4-978f-c2bcc5627f92" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_9345f233-dec0-41ca-834a-934612e1aca8" xlink:to="loc_dei_DocumentPeriodEndDate_5603d546-16f4-45a4-978f-c2bcc5627f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M YRUX[Q#E)#=?-Z33S[EUY7SVJ1)$Q]](@I"1*1;MT]]-'C4J-$^ LU^(YN
M%*]MV[;[[\R^"REX^5[[$JTKPG' NG&FD3^<[ZA#@'3BX<.'>\= UZY=[?WW
MW_=G !W8J%'C4CD*F0UR%(+#>B$762MDR#?)TB!KTHD21"O(5-:)ST+OTMP$
M.4X$BLCB^^]_8%VZ=/&10/0U:9<S9LST^Q[9P-X/C@+V/S*AJM:5"943(DA"
MN0+E@+#$VX2RPP#$LXD!BU(DO(]7D_0-E$&#!@V\QQ=2A*<LY=VLX15N4.*!
M'%W*P.;_;[[Y)B?T[[#[[KW;ZCQ>W9HVK&&M6]2POAUJVLS!#]N6F;7MR.*:
M=G+1S^W"HK\Q6_B';OR!V8+?3XU%?^((TY^;+7&$:=G?.]+D"-.*_W2DZ7I'
MFFXS6UO=;/VC9IN>=:3I5;.=K1UI^M3LX.=F1V>8G5IE=FYW29U2"4FJ1 HB
M6H@+.8(8D0)#A \CC%H.## ,&Q0YQE=J[9YSA*6N)PU!F4-J\50&(RR06]:I
M+ 0I*'Z, 'Z/W^<YP0 C(H4!5KOV8R6*O;XGUGC),8@A;'C/4>JD&%%G@:<:
M0^7 @8->B9<5E84@X8WFC.%]9FVR&9Q-4EN9/P@/]8 8J^G >,4XPE BD@AA
MQO@MZ^?@(<> ?^&%%_PZLJZ<]6SGECV# 4C#!]8*P^^EEU[*>E[2!Y[VP8,'
M>X</9P62A#&?+8*3@F<A1XD*4H\"\8=,X-DG[0KCE;.(,8M1RQG L";2"C'A
M?!#1P0@F,I=^)@,QBCJ>RF)P1_=PNC.#9P<#G,]#CB//'WSP(2\?GGCB"1^U
M>/;97_KW90\0N8#4X2B#,)/F1<T,WYG]Q;G@'.:[P1VML27=E'6#% 7' 226
M\PYAQ[%#)+QQX\:>/+)'(;$X@-"!K!ERE AZNAR-DJ.R$J2P3D&>AK7BV2&J
M%%TG=#'OPWOQ?LAZ]OR;;[[IHY)1^<J^A-@B)XDDAV8/^;Y>@@!$D(1R!9$C
MR!'>)=(^2/G L":%!H&+<8L"O>...TH)4+K"#M[,RY&B2T<=KK/KW>_=>LM-
M=O>=MUG->^^TEU^H99]U><F63&MM>Y:^YDC2 W9VX;^D2-&\WS&;\QMF1;_B
MQJ^Z__ZN&[_FQJ^[\;W4O\W]'V[\IAN_93;__W$$RI&KY3]UI*F:V<:ZCBB]
M9;:_ER-)4QQ)6FM6?*(D!8_TKLJC(*+>3Z("$%L,/T@!42*,,-8.;R/*]+;;
M;O/>R.C:822%M(]HM*@LZW<EHA1]3E#R(14OI>QO]N]"Z@G&&8H>Y8[Q3>MH
M<OFG3)E:2I(N%0VY'"H+0<(0(Q*# <K:9#,@*JPU9)-4&^8.CWXZV"<0 QIP
M].G3QT<',.[*^CF<_>@>"H9Z''/+<VZX(>4UY]FI_9'=O*0/]AC["\\Z$4NB
MY#@7L@5G$!(?G$S+EBWWD4'2YMJT:>O)$ 9L>C0HI,FEG\<KG<FK,;2OYIRF
MG]5P7L-ZA#7AO3FW? ^^$Z2)>ADB?GQGR#=$ \*1SXT!HG<2<89Q,!'1)3(&
M,<(I^/+++_OH-Z05XL-W#_H/&?9-<C2;M8K^;E2G?M,ZI=[MEE+YRGNS[\):
M(0_) B&R1!H>Z9)J!R]4)H@@";$CF@:",D>!X4$E'0MO$D83'>80GA2%DHN.
MYQ#ABA%;UG2K3 ;/#E&')Q][T-Y^[5D;U/,UFS6JN:V>7,?VSK[+3LS_3SLS
M[^_LPMP_2A$@"!$D:=8UEQ]%CCS-^SVSA7_FB-(_F:TB'>\1L\TO.J+4QA&E
MS\P.3S8[OL"1I35IJ7?YE;,=&F:$&I)41[%MWN"ER#NL'1$)&F&P=D2'(+;,
M;=QK%M=@/Z',(7%XT/%^TNP!0Y^T0+ITH<@Q9D-:5"BPOY37L[(0)(RQCS_^
M.)8VV9Q/#""\^QT[=O+IL,Q!.GA?B!DU"MV[=_>&.Q&^BMX#Y37PM%/G1$T-
M48+0*>]JSF!HI<P>#$TVB)J0LDCT%@.;*!4>>R)[U&:R-LPS!BN&;!RDLB('
M9X'OP7?" 4,4C 8$?&?J&XE.DIJ=?F:C;:@K F'=0N,:2!%U.D2^J"N"...T
M(*I*!.;))Y_TSAN:B$#>*WK>,QF0)_8=:\7^?_[YY_T90/901TQJ+H1^_?KU
MCBSM\O,2&G"(+ GY"!$D(78$Y8!Q3?T#$0>,!(I-";V3"X]")^\\1!Y"L3X&
M=AR>RRLIW. )N[?&75:OSL/6HFD=Z]RN@8W^K*$MF_B\[9Y?WP[-O\O.S/^Q
MV?P_<23)$9^BWW!$Z%MF,Z^Y])A%I.G[[F?_E_N=/S8C56\IJ7C7FJTA!8_N
M>(T<6:+!0]\46:).Z>P.-V$G+9_N4D)9H=A##0EI5-14X.W$,*%8EY0U4F$P
MR,+:03Z8UXI6U-^DQ#'R\4H3T2#EB&@2$1'2HGKV[.GK-MBO*')_AU9)YSL1
M)!&DLHYL"5+TXFOJ58B44+0/*1HZ=*@G]42HZ$R&MSXT/6%?!W(44E<K>BZR
M'7P/OA/I7CC12+DD]9+O3O2%U#N<-N&LA$8!%=D:/*P;I TYPAZ@J4&T80VI
MG:EF0[6\TP9RA/ZKK*26]P[.1]8*^<J^I':)"#+I=Y!"ZJO('F%>F!\U=A#R
M%2)(0NQ L6,\DG.,8J?PM%^_?LZP?L=[RYYZZJD2A7"G5WS18N!<$:,PHN2+
M#G?5[KC5[JU^ISU;MY9U:-O4)@S_R+Z8U]5V+7C)CB^\TQ&='SK"\P-'?G[;
M;(8C2#.NN?28"7GZCAM$FG[-;+8C2T6_93;G=\WF.<*T\*_,%O^CV>J[S#:]
M:+;[8[-#8YV5O<+LPF'+I^8-K!^>6+S5&+FT=L7 #I$^%%\H#(84A;7+5=0O
M;B4>TD:BN?;L1\@-7GARZ2F01HE#$$/[VG1C2P1)!.ER(PZ"%!HQ$,&%'$$"
M,#!Y+HXE'!/,:9"CH7O9U13I5X9QJ9K#5'W,W?Z\L;<@BS3V()V1I@#A(M2*
M(DA\/N\1R!'.)1Q+H<D0$?=H'6U(FZL,,O1*ZQ1=*[X7^Y+OR5[E3* _B-K3
ME8]&(E]\L=;/$_M<$/(-(DA"+(C>X8# H\8HY?&<YJ-&D*-GGWW6"TD4&T*T
MH@5ZM(BX9LU[[>4FSUNWSNULPH@NMG1R*]LYYQD[L^1N.[?P/ZQXWE]:<O;_
M= 3H>XX0.1(TW1&BZ==\\X!4S?RN(TW_PQ$F1Y86_8/9JFIF&WYIMH/4NX%F
MQ^::G=I@=FZ/8R?'G'5T+M7,(5E^RCW<8P09P*NW>O4:?]<%A;88UT2,\%#C
M&42IY\/ZQ3GX/N30T^&L7KUZ?K]"ZB'W7#X+T8?PGSQY\1XE$201I,N-3 A2
M*.(/=QAQ#DD=P^C'ZQ[J_8@Z0.ASF8I<&0;?FS-+!@+MJ-NT:>,;QI!^N&G3
M9J>']OLS&M)C<YW&!2$+CD%2DDG7I2,=SA92Z4@/#)U7(0]59=U"FF2XF@&2
MF+J'K*^7'W1 W;%CIQT^G&KGKGN4A'R!")(0"R!'>#HA1K3YI#,/J0_4J:0:
M,-3W77 PDA"4^: <HAZO:M7NL"<>KV5-'4GZL$US&_Y92T>27K<#RUO9L26/
MV]F%UUER_E\ZDO/[CNS\EB,_WS&;=DW9QHQ?<>/7'%'ZOMD<HDF.)"W]A=GJ
M^\TV<B$M7>_ZFAV9[B9RHV.;1QUC.54NM4G!<,#CF2)&JTL;,'#O!M$4HBH4
M^ =RA+++A_6+<V!H$@V#O#_PP .>S&.,DG9'NV'J!FAG3BW!D2-'2XTA$201
MI$N-3 @2>PHG!2E'FS>G]A678]/=D[T5HN^A5K.L36H*>2"/0KHLJ5RTGR:-
MC9;^U+N69S2)]:71"PX54B$'#!C@Y0?Z#WE" Z)H.^Z*GKOR&B&M/43_L ,@
M272^X_)@2"W=1*FM0[[&T>U1$.* ")*0-3"P\7A"CC &R)%',5#;$2X#Q7,4
MTK%""DA%"^X@O$O3[1Q)NN^^>ZUNG<>M?=N6-G%D-]NR<KCM7_Z>G5CZF"47
M_]1L_E^;S?Z_'4'Z5;.IUY1M3/N6&]]VO^.(TO3O.8+UVZEGS"/MSCUS136S
M];\TV]W5[.@<LW-['4DZDFH+7@YKQZ!>C"8,%#W3@ &/)UY9"H<A1M&ZAD(T
MR@)1#BV)V:^DP>"=QL#AUOIITZ;[R-KNW7N\0T $203I<B,3@A2] @$G$REC
MI"/1+C_4^H7H _NTD-+H,AV<V1"=8'YH84Y-%G4^X\:-\_/..65NX[@<^E((
M,I0]3Q,&/A=22S,)4LI".GFHT;S:.Z4*842[%X9[L2"V.$[9XW1AG#QYBB=)
MU'VJ:8.0#Q!!$JX*T9;/Y V'2T,A1W2GPR#@8CL*4/%T1N]FJ&@A?:41-9#O
MN><>>[E)(^O9O:O-FC;6ULSI;/L6O6+G5SQBB<7767+>WYC-="1GVG?=<*1G
MZK?*3I:B8_IO.*+T!XXHT=#A!K,-+YCMZ6EVI,CL))WN2+D[79)R%Y]R#VL8
M;FYG_3 D\'K20O?UUU_W#1AJUJQ9X>M2D0H]&%_</X*Q@Q*?-&FR]Q#CF:8!
M2:@Q$$'Z*D20RD:00EH=9Y']Q,]QT2OW_="VFSO@0EI658HZ9#*(4-!)$\<&
M^@>20C2<>\#8C[F(3(1(,D8]$>;QXR=8ERY=??09<L3[5/2\Y/-(D:1G?=,F
MY"OR@O3(HT=3%W<KW4ZH2(@@"5>%T#X5P16(T?SY"_PEA5P6BC>(]IZT4<8+
MG\DE@Q4QHO<^W'[[[?;T4T]:RQ;-K&OG]C9AV >V9E8[.[&^K9U;7=^*%]]D
MR:(_=R3I?SF2\WU'=AQ)FG+-U8^ICF#-<$1K%B3I[\R6<>EL7;.M[YKM'6!V
M=)XC2;N=%C[D)IX+3+/WJ@5R&QHQ4.- SCX%X-S:WJI5*U_C0"T.7KZ*7I=\
MV ]<I,F<$$F":(P>/<9[BB%'U-GA&!!!^BI$D+Z9($4O?26M#@,[=:EN;[^7
MZ-2&DPERA/%?:'5_<0\())$D2 GG$*<&72F94^XY@X#&78N$#(6 (0=(*^_2
MI8N7$^'J ]ZGHN<EGP?RA-3#>O7J^_/"WB=23_,&TNT@GX)041!!$JX*T?:S
M=#FCD)]BR]0EA4V<\?2XU:B1NJ PU*KD.SD*([PKBK:Z,^9JUZYE#9_[I77M
M^([-GM3+#FZ=9"<W=+!S*YZTQ/P?F<W^@2,XCB1-<41G\C49C&^G?G?J;SBB
MY9Y3]!=F\__%;*DC2AN;IDC2B=5F9W8XDG0DEJ8-T3NJJ#G" *?#4NO6K?W-
M[:P?=3BDU%5ECW6TVV$TY>[%%U_TQ?)<5$GQ/.0( TP$Z:L00?IF@H0L#??D
M<!;92Y]^^FG)O3A/^?36< ZK8EK6U8Y0ZX+>(>I&"W_(2N?.7?P=/#1:"00I
M+I*$$4\Z)$TT.G;LZ)O9D)8+28,<\3X5/2_Y/)B?T+R!]NVT/R>2Q 74I#,?
M/'@HEG42A$P@@B1\(Z)*A5QNO)T80(L6+?)Y\MQN3DH6GJ!"\)AAB(2\=E(
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M+-B6+=F626:4+;,DB\%B9F:TR&*6Q;9D2[*8++:8&8>AN^L_;]T^,U>CF='
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M[,;PAR0\N:Z$%W:6\-IQ$MF_2N3*R8J>B4HC[!_ -<;MTJ5+-9?- :1@I"H
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M';$; VM*>.23$C*_$Y[?T?SN'(F<.U#1,U%IQ!9I((?-%FG Z IB'SN E)P
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MGB(,*&X27C&H%BY<F%<J]-2IT]J@-J&%"SXGTRNS??&81#;/EO#,5@;$W&7
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M_O+3\FPAB(JNJNBGT[,/B&KB#$7?TXR7/>G$2=#B %*2"PJ:)I;0WH+P6%J
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MGU)7:1,W,U,E<F"=A%>,DM"$UR4TTH"D 0])J(<!2-VJQ6;T>T!"DQI)>,E
M"6^>)V$#DB*77=/8X@1J$?D5Y&70PX4]"74JB'WN %+E!D@8JN2G\?Y3ITZ3
M3ITZ:Q0GECF9]DXFOP0@QC=20AQ@1#&=]>LWR/[]!Y1^?.+$28VT4VJ:NQ,
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MFV^^J<Y7>F=1!8]H$N>4.8X'G1]V"9$LUI&>7!3-X>YPXB0(<0 IR04E@P+
MVX-!@R%WWWVQ+<5=5L5E>QH1Z2)T3D\.#+N9,V<ID(!GC%>4J%AEC1KY!<\<
M-)P>/7IJ$C<T!AHJ7KIX05(OG)'L\\>-%7Y(9,,LB4QK(^&>]Q@P4TW"G6\+
M?O#<;C7,;]PKX<%/27C1 (E\M%8DG!OMAU3Y<KQB+7A8J0)&?A\TIR"KDSF
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M<4GB64))T9"N7[]^"HSPB*+T:62(@JST35\+"-_$!8[2GSY]N@)6: @H;0P
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M(T!:MVZ]YE*24\CO!$4EHF\=?66XM]D/S D.I606'!&43"?:CF&-0PG:8KP
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M('WPP5K-26-/!!F=]TI[M]&\1*J"[=OWD<Y/,@L-2+DOH1JW:-%2]0CW8A
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MT,I?&-7L1:B>R1A!0B_@C-BW;Y_2"8G&L59!1FD]@/2@ J0&#1IHV>W" !)
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M4J3U'T0Z_%5DZ+,BBP>*[%LC<N6T2-H5D9S*4WS#V_]>U(CY))+P[KLK%)0
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M<>[9HV4!\T2BN+LXJQC?L2A3S7N3BP3E$&HO33=Q*'%W<\Z8MT0 2?:<X7S
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MT'U$M>E1"$C"V81^LG10_WX,>IT+6^^;K3E[CUZ .!2[=.F:5[0HR+Z*!<\
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M)\H!M6[+EJU*GT'I%4I1"^>*9*:(7#TK<FJ/R-I)(I,;B'3_BTA[ UY:_,
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M[JP97GY '?L.P!!KIY)]3_:BI>=B0!.UQ=,/!8\S0L0$IT7A9VOM#><,XQB
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MFOBS-N( 2.+\0[4C<NX57[ETPYZQ[Y^6EJ;O#[BDCP[SZ)6+]^Y% !^5O#P
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M7<BS_?<A]S+OP?L04>3=,.[9_[PS# 'N=H 1@  C. CJ%'<K;1$ 60!_G!,
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MMW!^*M3@98-[/8X-@\L_<U6MXLJ/^3.K_U G='R)W>:E#G#J>11+K(\LL?-
M\NR79>6?_*[L05H7GH-SW.!6Q01&]B#MUPQ)NB>:95)_H[CGI)R[:>^4]5Q
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M&+,W)]_1V,.DX*$>/"I#'/<PY0U(5[NQZ\"YKX[5NU)9[@F?TYR11I\>^(<
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M:49*)=5#0%7?J;P!J:[?I^?GYN]XV:B>%<WN=>3=#)];?T<5%K_550JU+XF
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M07+;#;E[@6DF2XV7==Z>";SX7:EI[=3?3<\(J@GT16_S#%4]!$,"$KJ)@ 0
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M'>@B A(     ) 0D     $@(2     "0$)      ("$@ 0   $!"0 (   "
MA( $      D!"0     2 A(     ) 0D     $@(2     "0$)      ("$@
M 0   $!"0 (   " A( $      D!"0     2 A(     ) 0D     $@(2
M  "0$)      ("$@ 0   $!"0 (   " A( $      D!"0     2 A(
M) 0D     $@(2     "0$)      ("$@ 0   $!"0 (   " A( $      D!
M"0     2 A(     ) 0D     $@(2     "0$)      ("$@ 0   $!"0 (
M  " A( $      D!"0     2 A(     ) 0D     $@(2     "0$)
M("$@ 0   $!"0 (   " A( $      D!"0     2 A(     ) 0D     $@(
M2     "0$)      ("$@ 0   $!"0 (   " A( $      D!"0     2 A(
M    ) 0D     $@(2     "0$)      ("$@ 0   $!"0 (   " A( $
M  D!"0     2 A(     ) 0D     $@(2     "0$)      ("$@ 0   $!"
M0 (   " A( $      D!"0     2 A(     ) 0D     $@(2     "0_!^>
3CN;6DR2P:@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 12,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Editas Medicine, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-4097528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11 Hurley Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">401-9000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EDIT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001650664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 12,  2025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="edit-20250812.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.editasmedicine.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="edit-20250812.htm">edit-20250812.htm</File>
    <File>edit-20250812.xsd</File>
    <File>edit-20250812_def.xml</File>
    <File>edit-20250812_lab.xml</File>
    <File>edit-20250812_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "edit-20250812.htm": {
   "nsprefix": "edit",
   "nsuri": "http://www.editasmedicine.com/20250812",
   "dts": {
    "inline": {
     "local": [
      "edit-20250812.htm"
     ]
    },
    "schema": {
     "local": [
      "edit-20250812.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "edit-20250812_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "edit-20250812_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "edit-20250812_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://www.editasmedicine.com/role/DocumentandEntityInformation",
     "longName": "0000001 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250812.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "edit-20250812.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.editasmedicine.com/role/DocumentandEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001650664-25-000123-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001650664-25-000123-xbrl.zip
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MTVKXS+<<M^H$ON<VV6!P<-.J!UYST&Q0*W#AKVHUJ%O-JA]:P<"O']:J@UI
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M:8CVM^40%\;()RCKE:^CA<&%2L8MZ'^D5VZ0$ !',E$RQ,B[ SB):.%$.-<
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MEQ7/G4^ ;046=P17G2%G@X7]?',+BM@@7-N2,*%L_O<;_5_FM/\?4$L#!!0
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MMA,?M.NL"33Z9K/M]+OVF+5>[P-ANZ(?S:-WKS;/Y*O_<OWNU?\!4$L#!!0
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ME I+;@?I0(7,P649(2F31$S*)>='N?VYM6VO/P_V81-G=9.PH75H8\XW\8O
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MR_D7DM+\/K[>N_^@.W3_O_5Z[S]02P,$%     @ =( ,6V=LN_=)&   A?P
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MN>XTVQU;H_#19H]/MZ3".C2Z33!7(IIW>Q_W8^92K6S3K1_(NF[01\E5V*8
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M:70M,C R-3 X,3(N:'1M4$L! A0#%     @ =( ,6RU"3WN  @  40@  !$
M             ( !<@\  &5D:70M,C R-3 X,3(N>'-D4$L! A0#%     @
M=( ,6ZE)1L?X @  <PL  !4              ( !(1(  &5D:70M,C R-3 X
M,3)?9&5F+GAM;%!+ 0(4 Q0    ( '2 #%MM[9]3TPH  +5<   5
M      "  4P5  !E9&ET+3(P,C4P.#$R7VQA8BYX;6Q02P$"% ,4    " !T
M@ Q;?%9&($D'  "/-P  %0              @ %2(   961I="TR,#(U,#@Q
M,E]P<F4N>&UL4$L! A0#%     @ =( ,6V=LN_=)&   A?P  !X
M     ( !SB<  &5D:71A<VUE9&EC:6YE<')E<W-R96QE87-E+FAT;5!+!08
1    !@ & ),!  !30      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>edit-20250812_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="edit-20250812.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001650664</identifier>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001650664</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Editas Medicine, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37687</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-4097528</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">11 Hurley Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Cambridge,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">02141</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">401-9000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">EDIT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-23">2025-08-12</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-24">2025-08-12</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
